Table 4.
Cryptococcal Antibody Tests Performed by Laboratory A, March 1, 2019–October 1, 2021
| No. (%) | |
|---|---|
| Total | 5009 |
| Result | |
| Negative | 4937 (98.6) |
| Positive | 5 (0.1) |
| Test not performed | 67 (1.3) |
| Median age (IQR), y (n = 4938) | 57 (42–68) |
| Sex (n = 4939) | |
| Male | 2699 (54.6) |
| Female | 2240 (45.4) |
| Ordering specialty (n = 4023) | |
| Family/general practice | 243 (6.0) |
| Hospital | 2347 (58.3) |
| Infectious disease | 296 (7.4) |
| Internal medicine | 329 (8.2) |
| Other | 808 (20.1) |
| Census region | |
| Midwest | 611 (12.2) |
| Northeast | 447 (8.9) |
| South | 2676 (53.4) |
| West | 1147 (22.9) |
| Unknown | 128 (2.6) |
| Reason for testing | 1972 (39.4) |
| Underlying conditions | |
| Cryptococcosis | 123 (6.2) |
| HIV | 312 (15.8) |
| Asymptomatic HIV | 35 (1.8) |
| Transplant | 18 (0.9) |
| Immune-mediated inflammatory disease | 43 (2.2) |
| COVID-19 | 3 (0.2) |
| Solid cancer | 45 (2.3) |
| Hematologic malignancy | 11 (0.6) |
| Chronic kidney disease or kidney failure | 78 (4.0) |
| Liver disease or liver failure | 24 (1.2) |
| Diabetes | 22 (1.1) |
| Symptoms and clinical findings | |
| Systemic | 123 (6.2) |
| Respiratory | 643 (32.6) |
| Abnormal imaging findings | 419 (21.2) |
| Central nervous system | 22 (1.1) |
Abbreviations: COVID-19, coronavirus disease 2019; IQR, interquartile range.